Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$17,500.00
The effects of forskolin and salbumatol on congenital myasthenic syndrome mouse model
EF 2021-22
Résumé
Muscle
contraction relies on the proper development and function of the
neuromuscular junction (NMJ), integral for the transmission of signals
from the central nervous system to the muscle. Inherited defects of the
NMJ comprise a group of rare disorders termed congenital myasthenic
syndromes (CMS). CMS are characterized by fatigable muscle weakness, often
in the facial area, and can be fatal through respiratory complications. Mutations
in the agrin/LRP4/MuSK pathway, found at the NMJ, are known to be
causative for CMS. The current treatments for individuals with these
subtypes of CMS are ephedrine or salbutamol. Previous research has shown
that salbutamol improves motor function and NMJ structure in zebrafish
models of CMS caused by mutations to MuSK and DOK7 and in a mouse model of
CMS caused by mutations to ColQ. However, ephedrine and salbutamol have
cardiac side effects and patients can become tolerant after years of
treatment. Our recent study demonstrates that forskolin, a more accessible
and specific treatment without the known side effects of ephedrine and
salbutamol, replicates the effects of salbutamol treatment in a zebrafish
model of CMS caused by mutation in MuSK. I
plan to test the effects of forskolin and salbutamol in a mouse model of
CMS caused by mutations to agrin, thus comparing a current and novel
treatment regimen. This will be the first time forskolin is tested in a
mouse model of CMS and salbutamol is tested in a mouse model with agrin
mutations. My study will help the research community further understand
whether forskolin would be an effective alternative for treatment of CMS.
We will also be testing analogues of forskolin that have been synthesized
to increase solubility and targeting in muscle cells to identify more
potential drug therapies.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
474338
Name
Ho Kelly Y
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The effects of forskolin and salbumatol on congenital myasthenic syndrome mouse model
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Behavioural Test; Beta Adrenergic Agonist; Cell; Congenital Myasthenic Syndromes; Drug; Forskolin; Mouse; Neuromuscular Disorder; Neuromuscular Junction; Salbutamol
Abstract
<html>
<head>
</head>
<body>
<span align="start" style="letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); display: inline !important; float: none"><font color="rgb(0, 0, 0)" face="Verdana, Arial, Helvetica, sans-serif" size="12.8px">Muscle
contraction relies on the proper development and function of the
neuromuscular junction (NMJ), integral for the transmission of signals
from the central nervous system to the muscle. Inherited defects of the
NMJ comprise a group of rare disorders termed congenital myasthenic
syndromes (CMS). CMS are characterized by fatigable muscle weakness, often
in the facial area, and can be fatal through respiratory complications.</font></span><font color="rgb(0, 0, 0)" face="Verdana, Arial, Helvetica, sans-serif" size="12.8px"><br align="start" style="letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255)"><span align="start" style="letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); display: inline !important; float: none">Mutations
in the agrin/LRP4/MuSK pathway, found at the NMJ, are known to be
causative for CMS. The current treatments for individuals with these
subtypes of CMS are ephedrine or salbutamol. Previous research has shown
that salbutamol improves motor function and NMJ structure in zebrafish
models of CMS caused by mutations to MuSK and DOK7 and in a mouse model of
CMS caused by mutations to ColQ. However, ephedrine and salbutamol have
cardiac side effects and patients can become tolerant after years of
treatment. Our recent study demonstrates that forskolin, a more accessible
and specific treatment without the known side effects of ephedrine and
salbutamol, replicates the effects of salbutamol treatment in a zebrafish
model of CMS caused by mutation in MuSK.</span><br align="start" style="letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255)"><span align="start" style="letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); display: inline !important; float: none">I
plan to test the effects of forskolin and salbutamol in a mouse model of
CMS caused by mutations to agrin, thus comparing a current and novel
treatment regimen. This will be the first time forskolin is tested in a
mouse model of CMS and salbutamol is tested in a mouse model with agrin
mutations. My study will help the research community further understand
whether forskolin would be an effective alternative for treatment of CMS.
We will also be testing analogues of forskolin that have been synthesized
to increase solubility and targeting in muscle cells to identify more
potential drug therapies.</span></font>
</body>
</html>
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ho, Kelly Y
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~